This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance ...
GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016 ® [Vaccinia Immune Globulin ...
GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration ...
Tuesday, H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The endorsement comes after the company announced a significant contract ...
Emergent BioSolutions Inc. announced a contract modification with the U.S. Department of Health and Human Services to provide additional doses of its smallpox treatment, CNJ-016® (Vaccinia Immune ...
Emergent BioSolutions receives a $62.4 million contract modification to supply Botulism Antitoxin for U.S. public health protection. Emergent BioSolutions Inc. announced the award of a $62.4 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results